eFFECTOR Therapeutics Appoints Mayank Gandhi, M.D., as Chief Business Officer

SAN DIEGO and REDWOOD CITY, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced it has appointed Mayank J. Gandhi, M.D., as chief business officer.